95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at 24 months
New data show liso-cel demonstrated high rates of durable responses and a consistent safety profile in a fifth cancer type, the most of any CD19-directed CAR T cell therapy
Additional liso-cel data at ICML 2025 further reinforce BMS’ commitment to unlocking the full potential of this therapy for patients
Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory disease. The new data will be presented at the 2025 International Conference on Malignant Lymphoma (ICML) in an oral presentation on June 19, building on positive topline results announced in February.
“Liso-cel achieved high, lasting response rates in patients with relapsed or refractory marginal zone lymphoma, underscoring the potential of this one-time therapy to significantly improve patient outcomes,” said M. Lia Palomba, M.D., TRANSCEND FL study investigator and lymphoma and cell therapy specialist, Memorial Sloan Kettering Cancer Center. “Currently, the median survival for patients with marginal zone lymphoma with multiple relapses is 3 to 5 years, signifying an urgent need for transformative therapies that can effectively address this hard-to-treat disease.”
The MZL cohort of TRANSCEND FL enrolled adults with relapsed or refractory disease treated with liso-cel in the third-line plus setting. Patients received treatment with liso-cel at a target dose of 100 x 106 CAR-positive viable T cells.
In efficacy-evaluable patients with relapsed or refractory MZL treated with liso-cel (n=66), liso-cel demonstrated clinically meaningful benefit, with high rates of durable responses. The overall response rate (ORR) was 95.5% (95% CI: 87.3-99.1; one-sided p<0.0001), with 62.1% of patients achieving a complete response (CR) (95% CI: 49.3-73.8; one-sided p<0.0001) by independent review committee per CT. With a median follow-up of 21.6, 23.8, and 24.5 months, respectively, the 24-month rates were 88.6% for duration of response, 85.7% for progression-free survival, and 90.4% for overall survival.
Liso-celexhibited a consistent safety profile, with low rates of severe cytokine release syndrome (CRS) and neurologic events (NE) with no new safety signals observed. Any grade CRS occurred in 76% of patients, with Grade 3 CRS occurring in 4% of patients and no Grade 4/5 CRS reported. Any grade NEs were reported in 33% of patients, with Grade 3 NEs occurring in 4% of patients and no Grade 4/5 NEs reported. The study will continue to evaluate ORR and safety in patients through the final analysis.
“MZL is an indolent disease but remains an area of high unmet need for patients who are relapsing and reaching later lines of treatment,” said Rosanna Ricafort, vice president, Senior Global Program Lead for Hematology and Cell Therapy, Bristol Myers Squibb. “We are proud to present for the first time the primary analysis data from the MZL cohort of TRANSCEND FL, underscoring our commitment to unlock the full potential of cell therapy to help patients living with relapsed or refractory lymphomas. As highlighted by the data at ICML, Breyanzi continues to cover the broadest patient eligibility of any CAR T for B-cell malignancies and demonstrates a safety profile consistent with clinical trials and in the real-world setting for approved indications.”
Additional key Bristol Myers Squibb data presentations on liso-celat ICML 2025 include:
Title: Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): impact of prior lines of therapy, bendamustine exposure, and disease progression ≤24 months of initial systemic therapy
Oral presentation: Thursday, June 19
Key findings: Results support the sustained clinical benefit and safety profile of liso-cel for patients with R/R regardless of POD24 status and prior bendamustine exposure with a trend for better outcomes in earlier lines of therapy.
Title: Matching-adjusted indirect comparison of lisocabtagene maraleucel versus epcoritamab in patients with third-line or later relapsed or refractory follicular lymphoma
Poster session: Thursday, June 19
Key findings: The data support liso-cel as an effective treatment for patients with third-line plus R/R FL, potentially offering improved efficacy over epcoritamab in this setting.
Title: Comparative outcomes of lisocabtagene maraleucel (liso-cel) versus an external control arm (ECA) in third-line or later (3L+) R/R follicular lymphoma (FL)
Poster session: Friday, June 20
Key findings: Liso-cel appeared to show better efficacy than SOC therapies in patients with third-line plus R/R FL, further supporting it as an important treatment option to improve patient outcomes in this setting.
Title: Optimizing post–chimeric antigen receptor T cell monitoring: evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience (recently presented at the American Society of Clinical Oncology meeting)
Poster session: Friday, June 20
Key findings: Results showed that most cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome events in patients treated with liso-cel occurred less than 2 weeks after infusion and were not severe, providing insight into the onset of these events across clinical trials and in the real-world setting.
Bristol Myers Squibb thanks the patients and investigators involved in the clinical trials.
